Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer
NCT00354679
Completed
RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of esophageal cancer by blocking bl... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/12/2016
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Esophageal Cancer
Register for Updates
A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma
NCT02256982
Terminated
This research study is evaluating the use of radiation therapy in combination with chemotherapy as a possible treatment for intrahepatic cholangiocarcinoma, a rare form of gastrointestinal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2016
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Unresectable Intrahepatic Cholangiocarcinoma, Resectable Intrahepatic Cholangiocarcinoma
Register for Updates
Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
NCT00625664
Completed
This is a randomized, open-label, multi-center study comparing the efficacy and safety of XRP9881 plus cisplatin to gemcitabine plus cisplatin in the first line treatment of locally advanced/metastatic urothelial tract or bladder cancer. The primary objective is to compare overall survival. Secondary objectives include comparisons of progression free survival, objective response rate, time to definitive deterioration of performance status, duration of response, time to definitive weight loss, an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/06/2016
Locations: Sanofi-Aventis Investigational Site Number 840068, Anchorage, Alaska +159 locations
Conditions: Urinary Bladder Neoplasms
Register for Updates
Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies
NCT01182168
Completed
The purpose of this study is to test the safety of gemcitabine and cisplatin plus Everolimus (also called RAD001) at different dose levels. We want to find out what effects, good and/or bad, this treatment has on you and your cancer. Gemcitabine and cisplatin are standard chemotherapy drugs that are commonly used to treat advanced urothelial cancer. Everolimus is a pill that works by shutting down some of the pathways in cancer cells that make tumors grow. Laboratory studies have shown that Eve... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2016
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer
Register for Updates
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
NCT00859339
Terminated
This trial will investigate the activity of sunitinib combined with cisplatin and gemcitabine followed by radical cystectomy in patients with Transitional Cell Carcinoma (TCC) of the Bladder.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2016
Locations: University of Florida, Gainesville, Florida +4 locations
Conditions: Transitional Cell Carcinoma of the Bladder
Register for Updates
Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer
NCT00506155
Completed
The goal of this clinical research study is to learn how well bladder cancer responds to a combination treatment with Avastin and M-VAC (methotrexate, doxorubicin, vinblastine, and cisplatin) before surgery to remove the tumor. Primary Objective: To estimate the response of patients with locally advanced urothelial cancer treated with neoadjuvant chemotherapy with a combination of Dose Dense Methotrexate, Vinblastine, Adriamycin, and Cisplatin (DD-M-VAC) plus Avastin followed by radical surger... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/01/2016
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Bladder Cancer
Register for Updates
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
NCT01296763
Completed
Patients whose pancreatic cancers have defects in the BRCA/Fanconi DNA repair pathway or other defects in homologous repair will have cancers that respond to olaparib when given in combination with the DNA damaging agents, irinotecan, cisplatin, mitomycin C (ICM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2016
Locations: The Johns Hopkins University School of Medicine, Baltimore, Maryland +1 locations
Conditions: Pancreatic Cancer
Register for Updates
Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer
NCT00216125
Completed
In a previous phase II study, patients with pathological stage IIIb (without pleural effusion) NSCLC were treated with concurrent cisplatin and etoposide plus thoracic radiotherapy followed by 3 cycles of consolidation therapy with docetaxel. Docetaxel was selected based upon a survival benefit in patients with recurrent NSCLC. This trial will evaluate the role of consolidation therapy with docetaxel in patients with unresectable stage III disease. The purpose of the trial is to evaluate surviv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2016
Locations: Medical & Surgical Specialists, LLC, Galesburg, Illinois +14 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer
NCT00234494
Completed
Cisplatin is a very important agent for the treatment of TCC as it has a single agent response rate of approximately 15%. However, it has been most important as a part of combination chemotherapy, MVAC initially and now in combination with gemcitabine. Single agent gemcitabine has demonstrated an overall response rate (ORR) of approximately 25%, including some complete responses (CR), with minimal toxicity in patients with advanced bladder cancer. Bevacizumab, a murine anti-human VEGF monoclonal... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2016
Locations: University of Chicago, Chicago, Illinois +10 locations
Conditions: Bladder Cancer
Register for Updates
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
NCT00390416
Completed
This study is being done to find out what effects a drug named/called bevacizumab has on patients and patients' tumors when given together with standard chemotherapy drugs. Making new blood vessels seems to be important for many tumors to grow. Bevacizumab is a new type of treatment for cancer that blocks the growth of new tumor blood vessels. In this study, the researchers will combine bevacizumab with chemotherapy drugs that are standard for the patient's disease and include cisplatin, docetax... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2016
Locations: Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey +4 locations
Conditions: Stomach Neoplasms, Esophageal Neoplasms
Register for Updates
Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer
NCT01565772
Terminated
This research study is looking at an alternative way of delivering radiation therapy with protons. Protons are tiny particles with a positive charge that can be controlled to travel a certain distance and stop inside the body. In theory, this allows better control of where the radiation dose is delivered as compared to photons. Information from other research studies suggests that proton radiation may help to reduce unwanted side effects from radiation and allow an increase in radiation dose tha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2016
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction
NCT00757172
Completed
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to kill tumor cells or stop them from growing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with panitumumab and rad... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2016
Locations: Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia +20 locations
Conditions: Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Register for Updates